An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Crysvita

Chemical Nameburosumab-twza
Dosage FormInjectable (subcutaneous; 10 mg/mL, 20 mg/mL, 30 mg/mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyUltragenyx Pharm Inc
Approval Year2018

Indication

  • Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Crysvita (burosumab-twza) Prescribing Information2019Ultragenyx Pharm
Document TitleYearSource
Clinical review report: burosumab (crysvita).2020CADTH
Pharmacoeconomic report: burosumab (crysvita).2020CADTH
Burosumab for treating X-linked hypophosphatemia in children and young people.2018NICE
Assessment report: crysvita.2017EMA